Publications

* Corresponding author    |   Also on Google Scholar and PubMed

 

2026

 

TwinPE delivered as RNA or VLP enables precise deletion of GAA repeats in the FXN gene.

Zhou X, Todeschini TC, Yu T, Wang R, Liu B, Collins A, Welch W, Ansodaria AV, Weng Z, Wolfe SA, Watts JK, Sontheimer EJ, Xue W.

Cell Insight. 2026 Sep;100368. sciencedirect.com/science/article/pii/S2772892726000714

 

Prime assembly with linear DNA donors enables large genomic insertions.

Liu B*, Petti A, Zhou X, Cheng H, Gao J, Yee M, Qiao Y, Zhang Y, Zhou L, Wolfe SA, Jiang T, Sontheimer EJ*, Xue W*.

Nature. 2026 Jun;654(8119):806-812. doi:10.1038/s41586-026-10460-4

 

p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy.

Zhou L, DeMarco KD, Murphy KC, Wu Z, Li J, Johnson C, Liu B, Giwa HK, Ma B, Bhalerao N, Li J, Jiang Z, Bai S, Parikh CN, Ye T, Simin K, Zhu LJ, Pitarresi JR, Wu H, Ruscetti M.

Cancer Discovery. 2026 Mar;16(3):571-591. doi:10.1158/2159-8290.CD-25-1212

 

2024

 

Targeted genome editing with a DNA-dependent DNA polymerase and exogenous DNA-containing templates.

Liu B, Dong X, Zheng C, Keener D, Chen Z, Cheng H, Watts JK, Xue W*, Sontheimer EJ*.

Nature Biotechnology. 2024 Jul;42(7):1039-1045. doi:10.1038/s41587-023-01947-w

 

2023

 

Template-jumping prime editing enables large insertion and exon rewriting in vivo.

Zheng C+, Liu B+, Dong X, Gaston N, Sontheimer EJ, Xue W*.

Nature Communications. 2023 Jun;14(1):3369. doi:10.1038/s41467-023-39137-6

 

2022

 

A split prime editor with untethered reverse transcriptase and circular RNA template.

Liu B, Dong X, Cheng H, Zheng C, Chen Z, Rodríguez TC, Liang SQ, Xue W*, Sontheimer EJ*.

Nature Biotechnology. 2022 Sep;40(9):1388-1393. doi:10.1038/s41587-022-01255-9

 

A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver.

Zheng C, Liang SQ, Liu B, Liu P, Kwan SY, Wolfe SA, Xue W.

Molecular Therapy. 2022 Mar;30(3):1343-1351. doi:10.1016/j.ymthe.2022.01.005

 

Modulating CRISPR/Cas9 genome-editing activity by small molecules.

Chen S, Chen D, Liu B, Haisma HJ.

Drug Discovery Today. 2022 Apr;27(4):951-966. doi:10.1016/j.drudis.2021.11.018

 

2021

 

D-dopachrome tautomerase contributes to lung epithelial repair via atypical chemokine receptor 3-dependent Akt signaling.

Song S, Liu B, Habibie H, van den Bor J, Smit MJ, Gosens R, Wu X, Brandsma CA, Cool RH, Haisma HJ, Poelarends GJ, Melgert BN.

EBioMedicine. 2021 Jun;68:103412. doi:10.1016/j.ebiom.2021.103412

 

2020

 

Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing.

Liu B*, Chen S, La Rose A, Chen D, Cao F, Zwinderman M, Kiemel D, Aïssi M, Dekker FJ, Haisma HJ*.

Nucleic Acids Research. 2020 Jan;48(2):517-532. doi:10.1093/nar/gkz1136

 

Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.

Liu B, Chen D, Chen S, Saber A, Haisma H.

Biochemical Pharmacology. 2020 Aug;178:114095. doi:10.1016/j.bcp.2020.114095

 

CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation.

Liu B, Diaz Arguello OA, Chen D, Chen S, Saber A, Haisma HJ.

PLoS One. 2020;15(5):e0232985. doi:10.1371/journal.pone.0232985

 

A novel histone acetyltransferase inhibitor A485 improves sensitivity of non-small-cell lung carcinoma cells to TRAIL.

Zhang B, Chen D, Liu B, Dekker FJ, Quax WJ.

Biochemical Pharmacology. 2020 May;175:113914. doi:10.1016/j.bcp.2020.113914

 

CRISPR/Cas9 for overcoming drug resistance in solid tumors.

Saber A, Liu B, Ebrahimi P, Haisma HJ.

DARU Journal of Pharmaceutical Sciences. 2020 Jun;28(1):295-304. doi:10.1007/s40199-019-00240-z

 

2019

 

CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment.

Liu B, Saber A, Haisma HJ.

Drug Discovery Today. 2019 Apr;24(4):955-970. doi:10.1016/j.drudis.2019.02.011

 

CX Chemokine Receptor 7 contributes to survival of KRAS-mutant non-small cell lung cancer upon loss of epidermal growth factor receptor.

Liu B, Song S, Setroikromo R, Chen S, Hu W, Chen D, van der Wekken AJ, Melgert BN, Timens W, van den Berg A, Saber A, Haisma HJ.

Cancers (Basel). 2019 Mar;11(4):455. doi:10.3390/cancers11040455

 

Histone deacetylase inhibitors sensitize TRAIL-induced apoptosis in colon cancer cells.

Zhang B, Liu B, Chen D, Setroikromo R, Haisma HJ, Quax WJ.

Cancers (Basel). 2019 May;11(5):645. doi:10.3390/cancers11050645

 

2015

 

A mutation-sensitive switch assay to detect five clinically significant epidermal growth factor receptor mutations.

Liu B, Zhou L, Wang Q, Li K.

Genetic Testing and Molecular Biomarkers. 2015 Jun;19(6):316-323. doi:10.1089/gtmb.2014.0329

 

A nanoscale mutation-sensitive on/off switch based assays for the detection of hepatitis B virus lamivudine-resistant mutations.

Sun A, Pu W, Zhou C, Zhang R, Liu B, Pan Y, Zhang J, Li P, Li K.

Journal of Nanoscience and Nanotechnology. 2015 May;15(5):3939-3943. doi:10.1166/jnn.2015.9277

 

CRISPR/Cas: a faster and more efficient gene editing system.

Liu B, Xu H, Miao J, Zhang A, Kou X, Li W, Zhou L, Xie HG, Sirois P, Li K.

Journal of Nanoscience and Nanotechnology. 2015 Mar;15(3):1946-1959. doi:10.1166/jnn.2015.9832